Lehman Brothers Holdings Inc said it plans to sue Marubeni Corp, Japan's fifth-biggest trading company, to recover "fraudulently misappropriated" funds that newspaper reports say may amount to more than US$250 million.
"We are confident in our legal claim, which we will pursue until we receive repayment from Marubeni," said Matthew Russell, a spokesman for New York-based Lehman, the fourth-largest US securities firm.
Lehman is seeking to recoup a loan to a fund controlled by a now-bankrupt unit of LTT Bio-Pharma Co, the Japanese biotechnology company, the Wall Street Journal reported on Saturday. The loan was secured by certificates from Marubeni, the Journal said. Marubeni, whose businesses range from importing petrochemicals to metals and minerals, denied wrongdoing, saying in a statement that the transaction involved forged documents and may also have involved former employees.
The Tokyo-based company said it was a victim of fraud and has asked for a criminal investigation. Spokesman Takashi Hashimoto declined to comment on Lehman's planned legal action.
Lehman loaned as much as US$250 million to the LTT Bio-Pharma unit, the Journal said. The company obtained as much as ¥40 billion (US$403 million) from investors, according to a report on Saturday in the Tokyo newspaper.
Russell, the Lehman spokesman, declined to say how much the firm is seeking to recover.
"After we became aware of the fraud, we launched a fact-finding investigation and then informed the appropriate authorities," Lehman said in an e-mailed statement on Saturday. "We are confident that we undertook all the appropriate measures on the transaction and will commence legal action against Marubeni."
Lehman officials said they have filed a criminal complaint with Japanese police, the Journal reported.
Another US brokerage may have recovered its investment in the deal, the Nikkei Shimbun newspaper reported on Saturday. Several other investors may have lost billions of yen, the paper said.
Asclepius Ltd was the LTT Bio-Pharma unit that obtained the Lehman loan, the Nikkei reported. The medical consulting company initiated bankruptcy proceedings on March 19. A spokesman for LTT Bio-Pharma couldn't be reached for comment.
LTT Bio-Pharma researches and sells drug-delivery systems to treat arteriosclerosis. The company went public in November 2004 on the Tokyo Stock Exchange Mothers market. The shares have fallen 82 percent in the past 12 months.
The planned legal action by Lehman in Japan comes as US regulators are investigating whether traders spread false rumors about the company's financial soundness to profit from a decline in its share price.
Lehman has tumbled 23 percent this month in New York trading.
MORE VISITORS: The Tourism Administration said that it is seeing positive prospects in its efforts to expand the tourism market in North America and Europe Taiwan has been ranked as the cheapest place in the world to travel to this year, based on a list recommended by NerdWallet. The San Francisco-based personal finance company said that Taiwan topped the list of 16 nations it chose for budget travelers because US tourists do not need visas and travelers can easily have a good meal for less than US$10. A bus ride in Taipei costs just under US$0.50, while subway rides start at US$0.60, the firm said, adding that public transportation in Taiwan is easy to navigate. The firm also called Taiwan a “food lover’s paradise,” citing inexpensive breakfast stalls
TRADE: A mandatory declaration of origin for manufactured goods bound for the US is to take effect on May 7 to block China from exploiting Taiwan’s trade channels All products manufactured in Taiwan and exported to the US must include a signed declaration of origin starting on May 7, the Bureau of Foreign Trade announced yesterday. US President Donald Trump on April 2 imposed a 32 percent tariff on imports from Taiwan, but one week later announced a 90-day pause on its implementation. However, a universal 10 percent tariff was immediately applied to most imports from around the world. On April 12, the Trump administration further exempted computers, smartphones and semiconductors from the new tariffs. In response, President William Lai’s (賴清德) administration has introduced a series of countermeasures to support affected
CROSS-STRAIT: The vast majority of Taiwanese support maintaining the ‘status quo,’ while concern is rising about Beijing’s influence operations More than eight out of 10 Taiwanese reject Beijing’s “one country, two systems” framework for cross-strait relations, according to a survey released by the Mainland Affairs Council (MAC) on Thursday. The MAC’s latest quarterly survey found that 84.4 percent of respondents opposed Beijing’s “one country, two systems” formula for handling cross-strait relations — a figure consistent with past polling. Over the past three years, opposition to the framework has remained high, ranging from a low of 83.6 percent in April 2023 to a peak of 89.6 percent in April last year. In the most recent poll, 82.5 percent also rejected China’s
PLUGGING HOLES: The amendments would bring the legislation in line with systems found in other countries such as Japan and the US, Legislator Chen Kuan-ting said Democratic Progressive Party (DPP) Legislator Chen Kuan-ting (陳冠廷) has proposed amending national security legislation amid a spate of espionage cases. Potential gaps in security vetting procedures for personnel with access to sensitive information prompted him to propose the amendments, which would introduce changes to Article 14 of the Classified National Security Information Protection Act (國家機密保護法), Chen said yesterday. The proposal, which aims to enhance interagency vetting procedures and reduce the risk of classified information leaks, would establish a comprehensive security clearance system in Taiwan, he said. The amendment would require character and loyalty checks for civil servants and intelligence personnel prior to
RSS